Windtree Therapeutics, Inc. · OTC:WINT
Windtree Therapeutics — Corporate Update (October 2016)
37 slides from Windtree Therapeutics's corporate update, Oct 25, 2016
Slide 1: Investor Conference Call
Se @Zwe@ WINDTREE Investor Conference Call October 25, 2016 NASDAQ:WINT
Slide 2: Forward Looking Statement
Forward Looking Statement To the extent that statements in this presentation are not strictly historical, including statements about the Company’s business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Compan
Slide 3: Focus on Execution for Value Creation
Focus on Execution for Value Creation End of phase 2 FDA& regulatory meetings Initiate priority life cycle studies Initiate RDS phase 3 201! Phase 2b results Phase 2a results in 26-28wk GA Transaction / Lung Deposition - Strategic Partnership Study results 201; Deliver positive phase 2 results Phase
Slide 4: Agenda
Agenda Lung Deposition Study in Non-Human Primates AEROSURF® Phase 2a Study (26-28 week gestational age) Update AEROSURF Phase 2b Study Update Financial Update Summary SB winvtRee
Slide 5: Lung Deposition Study in Non-Human Primates
Lung Deposition Study in Non-Human Primates
Slide 6: Pulmonary Drug Delivery Through Inhalation
Pulmonary Drug Delivery Through Inhalation Pulmonary drug delivery through inhalation can be very advantageous but comes with significant challenges: * Creating the appropriate particle size and aerosol concentration © Producing consistent drug output from the aerosol device * Delivering the drug th
Slide 7: Aerosolizing surfactant has been a particularly daunting task
Aerosolizing surfactant has been a particularly daunting task = Currently available liquid surfactants are generally effective for treating RDS but are administered via invasive intubation, which increases the risk of serious complications — thus the pursuit for a noninvasive approach = Surfactant c
Slide 8: Windtree's Proprietary Aerosol Delivery System (ADS) is a Novel Approach
Windtree’s Proprietary Aerosol Delivery System (ADS) is a Novel Approach Drug pumped through Capillary capillary Energy input * Delivering surfactant under pressure through a heated capillary has been shown to successfully create a consistent, controllable aerosol with particle sizes appropriate for
Slide 9: Aerosol Delivery System (ADS) Performance is Different
Aerosol Delivery System (ADS) Performance is Different ADS technology provides better output rate Aerosol output rate itput with Saline (mL/minute) Output with KL, Surfactant (30mg TPL/mL) a f= a [= 208 2 08 zoa Eoa 0x9 ox0 ove 00 oo Ca s - é e Saline output of ADS technology is close to KL, surfact
Slide 10: Aerosol Delivery System (ADS) Technology Delivers Optimal Particle Size
Aerosol Delivery System (ADS) Technology Delivers Optimal Particle Size ot ee ADS system produces more particles in the optimal 1 to 3um range than a commercially available vibrating mesh nebulizer * ADS aerosol particle size optimized for lung delivery deposition: MMD = 2.8um = Comparator nebulizer
Slide 11: Aerosol Delivery System Summary
Aerosol Delivery System Summary Aerosol Delivery System allows for a very well controlled and consistent KLa surfactant delivery system: * High output * Pre- and post-aerosolization characteristics of KLa surfactant are comparable * Consistent output rate and particle size from device to device * Co
Slide 12: Noninvasive Surfactant Delivery in the AEROSURF 2a Clinical Trial
Noninvasive Surfactant Delivery in the AEROSURF® 2a Clinical Trial Phase 2a Clinical Trial (29 to 34 wk GA) Initial Physiological and Efficacy Data Summary + AEROSURF produces clinical and physiological changes that are expected with surfactant therapy * AEROSURF may reduce the rate of nCPAP failure
Slide 13: Objective: Obtain Direct Evidence of Successful KL4 Surfactant Delivery
Objective: Obtain Direct Evidence of Successful KL4 Surfactant Delivery Using the Aerosol Delivery System (ADS) Can we demonstrate that aerosolized KL4 surfactant is actually getting into the lung? Rationale: * Use of non-human primates (cynomolgus macaques) — Nose, throat, & lung anatomy comparable
Slide 14: Lung Deposition Study Protocol Summary
Lung Deposition Study Protocol Summary * Invitro studies performed to validate that admixed technetium-99m (9°"Tc) travels with the aerosolized KL4 surfactant in a measurable and consistent manner * Radiolabeled KL4 surfactant aerosolized using Aerosol Delivery System (ADS), delivered via nasal cann
Slide 15: Lung Deposition Study - Distribution Information
Lung Deposition Study - Distribution Information nCPAP: NHP-3 Gamma Images Planar 1 SPECT Planar 2 igraphy provided qualitative images indicating wide spread distribution throug ntire lung SQ winDTREE we
Slide 16: Shell Number
Shell Number —_———__ Transverse view Coronal view Sagittal view S62 WINDTREE Fleming etal, Aerosol jr r sR Heng a AeiMesPumDrugDel 0122551129551 ap
Slide 17: Lung Deposition Study — Quantitative Analysis of Distribution
se @ 2 e Lung Deposition Study — Quantitative Analysis of Distribution Total Deposition Across 10 Equal Shells Lung Deposition (%) WINDTREE 16 8 . . Distribution of drug observed across all areas of the lung 1 2 3 4 after a3 to 10 min 5 6 7 8 Shell Number v
Slide 18: Lung Deposition Study — Quantitative Analysis of Distribution
Lung Deposition Study — Quantitative Analysis of Distribution Total Deposition By Inner and Outer Shell 60.0 Generally uniform distribution of drug 50.0 + -| observed between the = = 52% inner half (5 shells) of the ar \_ lung and the outer half 48% | o 300 [-} 2 5 = 200 8 10.0 00 Inner Outer Shells
Slide 19: Lung Deposition Study Summary
Lung Deposition Study Summary * The portion of aerosolized KL4 surfactant, delivered to the lungs using the Aerosol Delivery System (ADS) via nCPAP, is deposited throughout the lungs of NHPs within a few minutes * The aerosol is observed to be homogeneously deposited in all regions of the lungs * Th
Slide 20: Windtree as a Platform Company
Windtree as a Platform Company KLs surfactant + the innovative Aerosol Delivery System (ADS) technology enable a platform strategy that could enable potential prevention / protection, treatment, and delivery of therapeutics in an array of diseases pros I Fie intial Application cas a 7 Metastatic Bre
Slide 21: RDS Clinical Program Update
RDS Clinical Program Update
Slide 22: AEROSURF Fast Track Designation
AEROSURF® Fast Track Designation = In September 2016, Windtree announced that it had received a Fast Track designation by the FDA for its AEROSURF RDS program = The Fast Track program was created by the FDA to facilitate the development and expedite the review of new drugs that are intended to treat
Slide 23: RDS Development Program
RDS Development Program = Phase 2a 29-34 week gestational age (GA), 80 patients - completed = Phase 2b 29-32 week GA, up to 240 patients - ongoing = Phase 2a 26-28 week GA, up to 64 patients - ongoing = Lung Deposition Study - completed SQwinotree 23
Slide 24: Rationale for Separate Phase 2a Study in 26-28 week GA
Rationale for Separate Phase 2a Study in 26-28 week GA Gestational age (GA) has an important influence on many factors FDA recommended the younger GA group be studied separately The lower the GA (e.g. 26 weeks), the greater the incidence of complications of prematurity * Respiratory failure — higher
Slide 25: Phase 2a Trial in 26-28 Week GA — Trial Design
Phase 2a Trial in 26-28 Week Gestational Age (GA) — Trial Design = Objectives: * Safety and tolerability * Physiological data assessment for data indicating that aerosolized KL4a surfactant is being delivered to the lung and potentially reducing or delaying nCPAP failure = Design: * 30 min; 45 min (
Slide 26: Phase 2a Trial in 26-28 Week GA: Enrollment Update
Phase 2a Trial in 26-28 Week Gestational Age (GA) Enrollment Update Trial has taken longer than initially expected: * 26-28 week GA infants only represent an estimated 10% - 15% of RDS infants+ — Greater proportion of these infants are quickly intubated (even in delivery room) Site start-up has take
Slide 27: Phase 2a Trial: Safety and Tolerability Assessment
Phase 2a Trial in 26-28 Week Gestational Age (GA) Safety and Tolerability Assessment for Two Dose Groups (30 and 45 min)? = The safety and tolerability profile of AEROSURF® remains generally comparable to the nCPAP control group = The adverse events and serious adverse events (SAE) seen were expecte
Slide 28: Phase 2a Trial: Observations to Date
Phase 2a Trial in 26-28 Week Gestational Age (GA) Observations to Date = We have observed a positive early effect on prolonging the time to intubation but a more durable effect is needed to reduce nCPAP failure rates at 72 hours = Other Observations * High nCPAP failure rates in the control group —
Slide 29: Phase 2a Trial: Time to nCPAP Failure
Phase 2a Trial in 26-28 Week Gestational Age (GA) Time to nCPAP Failure for Two Dose Groups (30 and 45 min)* ‘Safety Review Committee Protocol 03-CL-1401 Data: 10/17/2016 Time until nCPAP Failure - Total Active and Control 1.00 080 0.60 040 020 0.00 ° 2 % 8 60 n Hours from Randomization Treatment —
Slide 30: Lessons learned in the phase 2a trial in 29-34 week GA
Lessons learned in the phase 2a trial in 29-34 week gestational age = We observed a positive early effect on prolonging the time to intubation in all five dose groups = While all doses delayed early intubation, the effect on rates of intubation were not observed in the first two dose groups = The th
Slide 31: Phase 2a Trial: Path Forward
Phase 2a Trial in 26-28 Week Gestational Age (GA) Path Forward Study is ongoing: Continue with more infants at the pre-designated higher dose(s) = Continue dose finding and confirmation through dose group 3 (and possibly dose group 4) * Assessment after dose group 3 expected later this quarter / ear
Slide 32: Original Plan: Phase 2b Trial in 26-32 Week GA
Original Plan: Phase 2b Trial in 26-32 Week Gestational Age (GA) 29-32 week GA — approximately n=180 2b Study: up to 26-28 wk GA — approx n=60 240 infants = Objectives: * Provide evidence of efficacy on an acceptable endpoint + Identify dose regimens for phase 3 study * Provide estimation of effect
Slide 33: Phase 2b Trial Moving Forward
Phase 2b Trial Moving Forward 29-32 week GA — approximately n= 240 Complete phase 2b with 29-32 week GA infants + focused solely on the larger market segment (older infants) Maintain current statistical power by continuing to study this group in up to 240 subjects: * Provides the opportunity for a s
Slide 34: Financial Update
Financial Update Cash and cash equivalents of $12.4 million as of September 30, 2016 — Q3’16 net operating cash burn of $8.4 million offset by $0.4 million of net proceeds from financings under the at-the-market (ATM) facility (159.1K common shares at an average price of $2.64 per share) $25 million
Slide 35: Conference Call Summary
Conference Call Summary Lung Deposition Study in Non-Human Primates AEROSURF® Phase 2a Study (26-28 week gestational age) AEROSURF Phase 2b Study Financial AEROSURF Fast Track designation SB winptRee
Slide 36: High Value-Creating Potential
High Value-Creating Potential Se we WINDTREE THERAPEUTICS” v Well characterized asset and target application in RDS ¥ Potentially transformative therapy for the important, acute neonatology market that has a clear unmet need and is growing Y Building data base of potential safety, clinical effect an
Slide 37: Striving to deliver Hope for a Lifetime!
“Striving to deliver Hope for a Lifetime!” S@ winptREe ve #
Windtree Therapeutics — Corporate Update (October 2016) on 6ix